Prognostic Role of Serum Lactate Dehydrogenase Beyond Initial Diagnosis: A Retrospective Analysis of Patients with Diffuse Large B Cell Lymphoma
- Authors
- Hong, Junshik; Yoon, Hyun-Hwa; Ahn, Hee Kyung; Sym, Sun Jin; Park, Jinny; Park, Pil-Whan; Ahn, Jeong Yeal; Park, Sanghui; Cho, Eun Kyung; Shin, Dong Bok; Lee, Jae Hoon
- Issue Date
- Aug-2013
- Publisher
- S. Karger AG
- Keywords
- Lactate dehydrogenase; Non-Hodgkin lymphoma; Diffuse large B cell lymphoma; Prognosis
- Citation
- Acta Haematologica, v.130, no.4, pp 305 - 311
- Pages
- 7
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- Acta Haematologica
- Volume
- 130
- Number
- 4
- Start Page
- 305
- End Page
- 311
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/65345
- DOI
- 10.1159/000353127
- ISSN
- 0001-5792
1421-9662
- Abstract
- Background/Aims: Baseline serum lactate dehydrogenase (LDH) level is a well-known prognostic factor in patients with non-Hodgkin's lymphoma; however, its role beyond initial diagnosis has not yet been defined. Methods: This study was conducted as a retrospective analysis of patients with diffuse large B cell lymphoma (DLBCL) treated with R-CHOP21, who had undergone regular checks for LDH during immunochemotherapy (n = 119) and during the posttreatment follow-up period after complete remission (CR; n = 100). The 119 patients were classified into 4 groups according to their baseline and change in LDH level during treatment, and an analysis of tumor response and survival was performed. The value of LDH as a predictor for relapse was evaluated among the patients with regular follow-up visits after achieving CR. Results: An increased LDH level during immunochemotherapy had no impact on tumor response or survival, and only the LDH status 'before' treatment was a prognostic marker. The sensitivity, specificity, positive predictive value and negative predictive value of serum LDH for detecting relapse after CR were 47.4, 86.5, 9.3 and 98.3%, respectively. Conclusion: The measurement of LDH level beyond initial diagnosis has no clear benefit in predicting disease progression or relapse in patients with DLBCL treated with R-CHOP21. Copyright (C) 2013 S. Karger AG, Basel
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 5. Others > ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.